Chierico FD, Masi L, Petito V*, Baldelli V, Puca P, Benvenuto R, Fidaleo M, Palucci I, Lopetuso LR, Caristo ME, Carrozza C, Giustiniani MC, Nakamichi N, Kato Y, Putignani L, Gasbarrini A, Pani G, Scaldaferri F. The solute transporter OCTN1/Slc22a4 affects disease severity and response to Infliximab in experimental colitis: role of gut microbiota and immune modulation. Inflamm Bowel Dis, 30(12): 2259-2270, 2024. Center for Diseases of Digestive System (CeMAD), Fondazione Policlinico Universitarioの研究グループが中心の共同研究